Biogen Idec / Tysabri

Biogen Idec took a beating today. Unfortunately, or fortunately I have a small position in this company. It will take some time to sort out all the data / info. For now, I'm holding onto the position, the downside is limited. The analysts have basically written off Tysabri in their models. I'm betting that Tysabri will eventually get back onto the market as a mono therapy use. So far the problem appears to be a combo therapy of Avonex and Tysabri.

This is a good example why one should diversify their portfolio. No one was expecting this news at all. This may be a good opportunity to look at other biotech issues. The market punished everyone in the group.